CorNeat Vision
- Company typePrivate
- Founded2016
- HeadquartersRa'anana, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
CorNeat Vision firmographics
Firmographics- Name
- CorNeat Vision
- Legal name
- CorNeat Vision Ltd.
- Website
- https://corneat.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
CorNeat Vision industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)
- akta.pro secondary industries
- Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF), Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI), Ophthalmic Regeneration (cornea/retina) (HLAAAGAK)
Keywords
Where CorNeat Vision is headquartered
LocationHeadquarters
- HQ city
- Ra'anana
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
CorNeat Vision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Medical Device Sales: Revenue from sale of FDA-cleared and regulatory-approved medical devices including the CorNeat EverPatch synthetic tissue substitute. Products sold directly to hospitals and surgeons for use in ophthalmic surgeries.
- CorNeat KPro Commercialization: Pre-commercial stage artificial cornea targeting corneal transplant market. Expected revenue from device sales and associated implantation tools upon full regulatory approval and market launch.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
CorNeat Vision product offering
Product offeringCore offering
CorNeat Vision develops and manufactures synthetic, tissue-integrating ophthalmic medical implants built on its proprietary EverMatrix™ biomaterial platform. The company sells the FDA-cleared CorNeat EverPatch+ scleral reinforcement matrix commercially, while the CorNeat KPro artificial cornea, CorNeat eShunt glaucoma drainage device, and EverPatch+ Shield remain in clinical/regulatory development for hospitals and ophthalmic surgeons treating corneal blindness, glaucoma, and ocular surface disease.
Product overview
CorNeat Vision offers an ophthalmic medical device portfolio consisting of four distinct products built on the proprietary EverMatrix™ platform. The core product is the CorNeat KPro artificial cornea, which uses EverMatrix technology to permanently integrate with the eye wall without donor tissue dependency. The company also markets the EverPatch+ line of synthetic, non-degradable tissue substitutes for ocular surface surgery, including the EverPatch+ Shield for glaucoma procedures. A third product, the CorNeat eShunt, is a glaucoma drainage device designed for severe and refractory cases. All products leverage the same EverMatrix tissue-integration technology to achieve seamless, permanent bonding with surrounding living tissue.
Differentiator
Problem solved
Functional benefit
Brands
- EverMatrix: The proprietary permanent tissue-integrating material technology that enables seamless integration of synthetic implants with living tissue.
- CorNeat KPro
- CorNeat EverPatch
- CorNeat eShunt
Products and services
- CorNeat EverPatch+ Synthetic, non-degradable tissue-integrating matrix (100μm non-woven polymer) for scleral reinforcement and ocular surface reconstruction. FDA 510(k) cleared and commercially available in the US from February 2024 for ophthalmic surgeons and hospitals.
- CorNeat KPro (Keratoprosthesis) Revolutionary artificial cornea that uses EverMatrix™ technology to permanently integrate with the eye wall, providing a 100% synthetic solution for corneal blindness without reliance on donor tissue. In clinical trials across Israel, France, Canada, the Netherlands, and Georgia for corneally blind patients not candidates for or who failed donor corneal transplantation.
- CorNeat eShunt Glaucoma drainage device that leverages EverMatrix™ technology to extend minimally invasive glaucoma surgery to severe and refractory patients. Currently in development.
Quantifiable outcome
- 78-year-old bilaterally blind patient regained sight immediately upon bandage removal, able to read text and recognize family members after CorNeat KPro implantation
- +4 more outcomes
Companies that use CorNeat Vision
Customer profileNamed customers8 records
Segments1 record
Ideal customer profiles2 records
CorNeat Vision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
CorNeat Vision partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- LiveUcorePartnership with LiveU to develop Remote Surgeon Virtual Presence (RSVP) solution enabling live wet-lab training for surgeons during COVID-19 travel restrictions. The RSVP technology enabled initiation of Canadian clinical site for CorNeat KPro implantations by providing real-time 3D HD video training without physical presence.
- AlconcoreJoint venture with Alcon and LiveU to develop RSVP solution for remote surgeon training. Alcon provides ophthalmic market expertise and distribution network. The partnership enabled clinical trial expansion despite COVID-19 travel restrictions.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
CorNeat Vision competitors and assessment
Company assessmentDirect peers
- CorneaGen: CorneaGen is a leading provider of corneal tissue for transplantation in the US and a direct adjacent peer in addressing corneal blindness. CorNeat's KPro competes against donor tissue as the alternative solution to the same patient population.
- Glaukos Corporation: Glaukos is a direct peer in ophthalmic surgical implants, particularly for glaucoma drainage/MIGS devices (competing with CorNeat eShunt) and corneal health products. Both companies develop novel implantable devices for ophthalmology using proprietary biomaterial platforms.
- iSTAR Medical: iSTAR Medical develops ophthalmic implants using proprietary biointegrating materials (STAR material) for glaucoma surgery—closely paralleling CorNeat's EverMatrix tissue-integration approach. Both target the MIGS and refractory glaucoma segments with novel material science.
Broad incumbents
- Alcon: Alcon is the world's largest ophthalmic medical device company and a strategic partner of CorNeat. As a broad incumbent, it competes across all ophthalmic surgical categories and provides distribution/training infrastructure referenced in CorNeat's GTM.
- Bausch + Lomb: Bausch + Lomb is a broad incumbent in ophthalmic pharmaceuticals and surgical devices, with competing products across cataract surgery, glaucoma, and corneal health segments where CorNeat's portfolio competes.
Emerging players
- TissueTech: TissueTech develops regenerative tissue-based products for ocular surface and wound healing applications. Competes indirectly with CorNeat EverPatch+ in the ocular surface reconstruction market using biological amniotic membrane technology.
- Sanbio: Sanbio is developing regenerative cell therapies for ophthalmology and other indications, including corneal applications. An emerging player in regenerative ophthalmology with partial overlap in patient populations targeted by CorNeat KPro.
- Aurion Biotech: Aurion Biotech is an emerging player in regenerative ophthalmology developing cell therapies for corneal endothelial disease. Targets overlapping corneal blindness patient population with novel regenerative approaches, partially overlapping with CorNeat KPro's addressable market.
- Kedalion Therapeutics: Kedalion Therapeutics develops novel ophthalmic drug delivery devices for the eye—an emerging player in ophthalmic innovation that shares the broader ophthalmic medical device space with CorNeat's portfolio.
Regional players
- BostonSight: BostonSight develops PROSE scleral lens devices and treatment for ocular surface disease—overlapping with CorNeat EverPatch+ in addressing ocular surface conditions. Both serve patients with severe ocular surface disease and corneal damage.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
CorNeat Vision social profiles
Digital presenceCorNeat Vision compliance and trust
Trust signalCompliance5 records
CorNeat Vision financial estimates
Financial estimateRevenue estimate
Valuation estimate
CorNeat Vision leadership team
Management profileNumber of profiles
Profiles6 records
CorNeat Vision funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CorNeat Vision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CorNeat Vision
What does CorNeat Vision do?
CorNeat Vision develops and manufactures synthetic, tissue-integrating ophthalmic medical implants built on its proprietary EverMatrix™ biomaterial platform. The company sells the FDA-cleared CorNeat EverPatch+ scleral reinforcement matrix commercially, while the CorNeat KPro artificial cornea, CorNeat eShunt glaucoma drainage device, and EverPatch+ Shield remain in clinical/regulatory development for hospitals and ophthalmic surgeons treating corneal blindness, glaucoma, and ocular surface disease.
Is CorNeat Vision a public or private company?
CorNeat Vision is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CorNeat Vision founded?
CorNeat Vision was founded in 2016. It employs 11 to 50 people.
Where is CorNeat Vision based?
CorNeat Vision is headquartered in Ra'anana, Israel, in the Middle East region.
How does CorNeat Vision make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are corNeat KPro Commercialization.
Who are CorNeat Vision's main competitors?
Direct peers on record are CorneaGen, Glaukos Corporation and iSTAR Medical. Broad incumbents are Alcon and Bausch + Lomb. Emerging players are TissueTech, Sanbio, Aurion Biotech and Kedalion Therapeutics. BostonSight is listed as a regional player.
Does CorNeat Vision have an API?
No public API is recorded for CorNeat Vision.
What industry is CorNeat Vision in?
CorNeat Vision's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAK, Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery), with a secondary code of HLAKAKAF, Cornea, External Disease & Refractive Surgery (LASIK/PRK). Its NAICS code is 339115 and its SIC code is 3842.